View Older Stories

Mar 19, 2026 06:12AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $30 at Guggenheim

Mar 5, 2026 06:51AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $34 at H.C. Wainwright

Mar 3, 2026 08:05AM Amylyx Pharmaceuticals (AMLX) files mixed shelf

Mar 3, 2026 07:00AM Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q4 EPS by 4c

Mar 2, 2026 04:06PM Stifel Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy

Feb 10, 2026 06:52AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $28 at H.C. Wainwright

Jan 8, 2026 01:32PM Amylyx Pharmaceuticals inc. (AMLX) Remains a Top 2016 Pick at Mizuho

Jan 2, 2026 10:00PM Here are Mizuho's top Biotech pick for 2026

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Dec 5, 2025 09:00AM Amylyx reports early safety data for ALS drug AMX0114

Nov 10, 2025 06:49AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $20 at H.C. Wainwright

Nov 6, 2025 07:03AM Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q3 EPS by 8c

Nov 4, 2025 07:45AM Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 28, 2025 08:27AM Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 21, 2025 10:53AM Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 15, 2025 08:50AM Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 10, 2025 11:08AM Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 7, 2025 03:12PM Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Oct 3, 2025 05:05AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $16 at BofA Securities

Sep 15, 2025 07:24AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $25 at Guggenheim

Aug 27, 2025 01:15PM Goldman Sachs Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)

Aug 27, 2025 07:05AM Amylyx discontinues AMX0035 trial for progressive supranuclear palsy

Aug 27, 2025 05:40AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $12 at Mizuho

Aug 7, 2025 07:00AM Amylyx Pharmaceuticals, Inc. (AMLX) Reports In-Line Q2 EPS

Jul 14, 2025 03:41PM TD Cowen on Amylyx Pharmaceuticals inc. (AMLX): 'continue to see AMLX as undervalued for the potential of avexitide alone'

Jul 14, 2025 08:19AM Citi on Amylyx Pharmaceuticals inc. (AMLX): 'we think avexitide is well positioned to demonstrate success'

Jul 10, 2025 02:23AM Goldman Sachs Resumes Amylyx Pharmaceuticals inc. (AMLX) at Buy

Jun 24, 2025 06:09AM Guggenheim Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy

Jun 17, 2025 05:17AM Citi Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy

Jun 11, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)

Jun 3, 2025 07:01AM Amylyx Pharmaceuticals (AMLX) Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

May 30, 2025 05:31AM TD Cowen Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy

May 12, 2025 07:01AM Amylyx Pharmaceuticals (AMLX) Announces Positive Long-Term Results from Phase 2 HELIOS Trial of AMX0035

May 12, 2025 06:58AM Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $16 at H.C. Wainwright

May 8, 2025 07:01AM Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q1 EPS by 20c

Apr 30, 2025 07:03AM Amylyx Pharmaceuticals (AMLX) Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Apr 7, 2025 05:32AM Mizuho Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform

Mar 4, 2025 07:32AM Amylyx Pharmaceuticals (AMLX) Files $300M Mixed Shelf

Mar 4, 2025 06:00AM Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q4 EPS by 1c

Jan 21, 2025 09:00AM Amylyx Pharmaceuticals (AMLX) Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Trial

Jan 10, 2025 08:27AM Amylyx Pharmaceuticals (AMLX) Announces Pricing of Public Offering of Common Stock

Dec 6, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)

Dec 4, 2024 07:32AM Amylyx Pharmaceuticals (AMLX) Announces Pivotal Phase 3 LUCIDITY Trial Design for Avexitide

Nov 21, 2024 05:09AM Goldman Sachs Reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)

Nov 18, 2024 03:31AM Baird Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform

Nov 7, 2024 07:02AM Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 37c

Oct 23, 2024 06:10AM BofA Securities Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Buy

Oct 18, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)

Oct 18, 2024 05:46AM Leerink Partners Reiterates Market Perform Rating on Amylyx Pharmaceuticals inc. (AMLX)

Oct 17, 2024 09:01AM Amylyx Pharmaceuticals (AMLX) Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

View Older Stories